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Abstract 
The effect of heat on the follicular absorption of drugs into the skin has not previously been 
investigated. In comparison to drug delivery across the continuous stratum corneum (SC), 
follicular absorption is known to be relatively rapid and therefore the use of short durations of 
heat may be particularly useful for enhancing drug delivery to the hair follicles, as well as being 
practical for patients to use. In this study erythromycin has been used as a model drug and the 
combined use of heat and chemical penetration enhancers was found to be able to 
synergistically increase the penetration of erythromycin into human skin via the follicular 
route.  Moreover durations of heat application as short as 10 minutes in combination with 
particular enhancer systems were found to be sufficient to significantly increase erythromycin 
delivery to the skin.  Overall the data indicate that the use of heat with chemical penetration 
enhancers offers a potentially valuable strategy for delivering drugs via the follicular route.    
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Delivering drugs into the hair follicles and their associated pilosebaceous units is highly 
desirable, including for example in the treatment of conditions such as acne and alopecia. The 
pilosebaceous units are filled with sebum, which is secreted by the sebaceous glands into the 
hair duct and then excreted to the surface of the skin [1]. In addition to protecting the body 
from microbial infection and acting as a natural emollient, sebum is believed to have the ability 
to interact with topically applied substances on the skin surface and in the upper part of the 
follicular duct, thus potentially influencing transport of drugs across these appendages of the 
skin [2, 3]. Focusing drug delivery to the hair follicles for the treatment of conditions such as 
acne should not only reduce the need for systemic administration of drugs with their associated 
systemic side effects but may also help to reduce side effects such as skin irritation. The effect 
of heat on improving drug delivery in general across the skin is well established [4, 5], however 
its ability to enhance drug delivery to the hair follicles is as yet untested. Previous literature 
has reported that the viscosity of human sebum is reduced by approximately two-fold, as the 
temperature of the tissue is increased from 26.5 to 38 °C [6], suggesting that as a penetration 
enhancement strategy, heat may have particular potential to increase follicular drug delivery 
by rendering the sebum more permeable to the transport of drugs. Moreover given the relatively 
rapid delivery of drugs across the hair follicles in comparison to the continuous SC [7], short 
durations of heat application may enhance drug delivery to the hair follicles to a greater extent 
than the continuous SC, preferentially directing drug delivery to these locations in the skin. A 
number of chemical penetration enhancers have been shown to interact with sebum raising the 
possibility of using these two penetration enhancement strategies, heat and chemical 
penetration enhancers together, to significantly increase follicular drug delivery [8]. To test this 
hypothesis erythromycin, a topical antibiotic used in acne treatment was selected for use in this 
study as a model drug along with a range of chemical penetration enhancers to investigate 
whether skin absorption and in particular follicular drug transport could be improved using a 
combined approach with heat.  
Materials and Methods 
Materials 
Erythromycin (Ph. Eur. grade) was obtained from Sigma-Aldrich (Gillingham, UK). Methanol 
(99.9%), acetonitrile (99.9%), absolute EtOH (99.5%), phosphoric acid (≥ 85%), formic acid 
(98-100%), (all HPLC grade), sodium hydroxide pellets (≥ 97%), hydrochloric acid (HCl) ACS 
reagent, acetic acid (≥ 99.7%), sodium dihydrogen phosphate (99%), phosphate buffer solution 
(PBS) tablets, hexane (≥ 97%) and IPM (96%) and ammonium formate (99%) were supplied 
by Fisher Scientific (Loughborough, UK). 14C-erythromycin (0.1 mCi/mL, ethanolic solution, 
99% purity) was sourced from American Radiolabeled Chemicals (St. Louis, USA). IPM 
(96%) and scintillation cocktail, ScintiSafe 3, were supplied by Fisher Scientific 
(Loughborough, UK). Transcutol (TC, 99.9%) and propylene glycol dipelargonate (DPPG, 
96%) were supplied by Gattefossé. Diisopropyl adipate (DPA, 99%) was obtained from Croda. 
The 2-octyl cyanoacrylate glue was sourced from Adhezion Biomedical (Wyomissing, USA). 
Soluene® 350 tissue solubiliser was obtained from PerkinElmer (Boston, USA).  
High Performance Liquid Chromatography (HPLC) 
Quantitative analysis of erythromycin for saturated solubility experiments and infinite dose 
Franz cell studies was performed using HPLC with an Agilent 1260 infinity system and a 
Phenomenex, Gemini™ C-18, 150 mm x 4.6 mm, 5 µm particle size. An isocratic mobile phase 
of 60: 40 phosphate buffer (20 mM PBS, adjusted to pH 7.5, using sodium hydroxide solution 
1M): acetonitrile was used. The UV detection wavelength, flow rate and injection volume were 
205 nm 1.2 ml/min and 100 µL, respectively. The retention time of erythromycin under these 
conditions was approximately 13 min. The HPLC methods were validated for linearity, 
precision and accuracy according to the ICH guidelines [9]. The calibration curve produced 
was linear over the concentration range 1–100 µg/ml, with a coefficient of determination (r2) 
of 0.99978. The limits of detection (LOD) and quantification (LOQ) were 2.1 and 6.4 µg/mL 
respectively. Intra- and inter-day precision (% RSD) for three standards representative of high, 
medium and low drug concentrations ranged from 0.5 to 0.9% and 0.4 to 1.4% respectively. 
Accuracy of the same three concentrations ranged between 98.7 and 100.1%. 
Liquid Scintillation Counting 
Quantitative analysis of erythromycin for cyanoacrylate biopsy and finite dose Franz cell 
studies was performed using radioactivity. Samples containing the radiolabelled drug (14C-
erythromycin) were analysed in a liquid scintillation counter (Beckman LS 6500), after 
addition of 4 mL of scintillation cocktail. The limit of quantification (LOQ; 39 disintegration 
per minute; dpm) of the method was calculated as the mean concentration of the blank (n=7) 
plus 10 times the standard deviation of the blank (4 mL of scintillation fluid) [9]. 
Erythromycin saturated solubility and stability determination  
The saturated solubility of erythromycin in a range of solvents including chemical penetration 
enhancers was determined using HPLC. An excess of erythromycin was added to vials 
containing the relevant solvent and the samples were stirred for 24 h at room temperature (21 
± 2°C) or the in a water bath at the temperature of interest, following the formation of a drug 
suspension. For aqueous systems the pH of the solutions was checked pre and post-saturation. 
Prior to the HPLC analysis, each sample was filtered using 0.2 µm PTFE filters (Fisher 
Scientific, UK) and following this the filtrate was diluted with mobile phase.  
In vitro drug penetration into human skin 
Human skin preparation   
Human scrotal skin was obtained from white European male donors with ethics approval 
granted by the National Research Ethics Service (NRES) Committee London, Camberwell St 
Giles (10/H0807/51). Subcutaneous fat was carefully removed from the skin samples using 
forceps and a scalpel within Class 2 laminar flow cabinet. The skin was stored in a freezer at -
20 °C until it was needed for experimental work.  
Preparation of test formulations for infinite dose Franz cell studies 
A series of saturated solutions of erythromycin were prepared by adding an excess of drug 
(determined on the basis of the solubility data) to each of the following vehicles: IPM, DPPG, 
DPA, EtOH, TC, PBS and TC: DPPG (50:50). The suspensions were then allowed to stir for 
24 h at the temperature of the membrane it was applied to (32 and 45 °C), prior to dosing the 
Franz cells.  
Preparation of test formulations for cyanoacrylate biopsy and finite dose Franz cell studies   
To prepare the formulations spiked with radiolabelled drug, 14C-erythromycin in EtOH (0.1 
mCi/mL) was transferred to a glass vial and the solvent evaporated at ambient temperature; the 
test formulations were then individually added to the deposited crystals. After stirring at room 
temperature, the homogeneity of each formulation was checked by transferring aliquots 
corresponding to either infinite (100 µl/cm2) or finite doses (10 µl/cm2) applied in the in vitro 
studies, from the top, middle and bottom of the formulation, into individual scintillation vials. 
The radioactivity of each sample was quantified using a liquid scintillation counter to confirm 
whether the homogeneity was within ±10% of the target radioactivity.  
Erythromycin penetration studies: epidermal, dermal and receiver fluid drug recovery 
Sections of full thickness skin were mounted, SC side up, in individually calibrated unjacketed 
upright Franz type diffusion cells with an average receiver volume of 2.7 mL and an average 
surface area of 0.6 cm2. Skin sections from different skin donors were allocated to experiments 
in a manner that ensured equivalent use of the different donors across the experiments. The 
receptor compartments were then filled with PBS (pH 7.4) and the cells placed on a stirring 
plate placed in a waterbath (Grant Instruments, UK). The receptor fluid was continuously 
stirred using a small magnetic bar, during the whole duration of the experiment. After allowing 
the skin to equilibrate with the receiver fluid for 0.5 h, 1 mL of an erythromycin suspension 
was introduced into the donor chamber. Franz cells (n=6 for each formulation) were occluded 
to prevent solvent evaporation and immersed in waterbaths controlled at 37 and 50 °C so that 
the skin temperatures obtained were 32 and 45 °C respectively. These temperatures were 
monitored throughout the duration of the study using a digital thermometer, with a type K probe 
(Fisher Scientific, UK). At 24 h, the receiver fluid was withdrawn and transferred to a glass 
vial, prior to HPLC analysis. In addition to running the Franz cell experiments for 24 hours 
additional experiments were conducted for a shorter duration (1 hour).  
At the end of the experiments, the cells were dismantled and the skin was secured on the bench. 
Any residual formulation was then removed from the surface of the skin by wiping it with 
alternate wet (with mobile phase) and dry cotton buds a total of 4 times. The skin was wrapped 
in aluminium foil and placed in deionised water at 60 °C, for one minute in order to heat-
separate the epidermis from the dermis [5, 10]. The epidermis and the remaining dermis were 
transferred to individual glass vials to which 1 mL of the extraction media (40: 60 acetonitrile: 
PBS, pH 7.5) was added. These samples were left in a sonicator for 15 minutes and then 
transferred to a roller mixer overnight. The extraction fluid left in contact with epidermis and 
dermis was assessed using the HPLC method developed for the quantification of erythromycin. 
Prior to HPLC analysis, the samples were filtered using 0.22 µm PTFE 
(polytetrafluoroethylene) syringe filters.  
Effect of different times of heat application on drug delivery 
Separate Franz cells diffusion studies were carried out for 1 hour using the method described 
above, to test the effect of different heating exposure times on follicular transport. The cells 
were initially placed in a waterbath (Grant Instruments, UK) set at 37 °C and allowed to 
equilibrate for 0.5 h, in the presence of receiver fluid (PBS, pH 7.4). The temperature of the 
skin was then increased up to 45 °C by placing the Franz cells in a different waterbath that was 
set at 50 °C, prior to dosing the donor chamber of each cell with 1 mL of saturated solution of 
erythromycin in DPPG. The Franz cells (n = 6, for each heating treatment) were then occluded 
and left in the waterbath set at 50 °C for 5, 10 and 20 minutes respectively. At completion of 
each individual heating treatment, the cells were moved to a second waterbath (Grant 
Instruments, UK) previously set at temperature of 37 °C. After the allotted time (1 h), the 
receiver fluid was taken (and analysed by HPLC) and the cells were dismantled to remove the 
skin; the amount of drug penetrated into epidermis and dermis was then assessed, as described 
above. 
Tape stripping studies with cyanoacrylate biopsy of the hair follicles  
Tape stripping experiments were performed using skin mounted in Franz-type diffusion cells 
as previously described. The donor chamber of each cell was dosed with 100 µl/cm2 of a 
saturated solution of erythromycin, previously spiked with radiolabelled drug. This dose is the 
minimum required for infinite dose testing conditions; as recommended in the Organisation for 
Economic Co-operation and Development (OECD) guidelines for skin absorption in vitro tests 
[11]. Franz cells (n = 6) were then occluded and left in the waterbath, for a total duration of 1 
h. The amount of drug penetrated into and through the skin was measured when the temperature 
of the membrane was maintained at 45 °C for 10 minutes (and 50 minutes at 32 °C) compared 
to when no additional heat was applied (32 °C for 1 hour).  
A multi-step recovery process was utilised to analyse the delivery of erythromycin in different 
skin layers and in the appendages. At the end of the diffusion experiment, the receiver fluid 
was taken and then transferred to scintillation vials.  The Franz cells were dismantled and the 
skin was secured to the bench. The donor and receiver chambers were each wiped down using 
alternate wet (with receiver fluid) and dry cotton buds a total of 4 times. The cotton buds used 
to recover the drug from receiver and donor chamber were then pooled and collected into 
separate scintillation vials. Next the skin was wiped with dry cotton buds and two tape strips 
(Scotch® Tape strips, 3M Center, USA) were taken [12] to recover unabsorbed formulation 
left on the surface (both cotton buds and tape strips were pooled and added to the same 
scintillation vial). The ‘differential tape stripping’ approach that was used in the present work 
to recover the drug from the appendages involved first removing the SC by tape stripping (10 
tape strips). Following this, a drop of 2-octyl cyanoacrylate glue (Adhezion Biomedical, USA) 
was applied on the viable epidermis, allowed to spread and then the bottom of a glass vial 
(Fisher Scientific, Loughborough, UK) was pressed against the surface of the viable for either 
0.5, 2 or 5 minutes; within this time the glue polymerizes and adheres to the SC. The glass vial 
was gently lifted and peeled from the skin [13] and then directly transferred to a scintillation 
vial. Comparative tape stripping experiments were also performed using the same procedure 
as described above with the exception that the cyanoacrylate glue was not used. To each of the 
scintillation vials containing samples for analysis, 4 mL of scintillation fluid was added. The 
viable epidermis and dermis from each of the skin samples were separated mechanically using 
tweezers and then digested in presence of 4 mL of Soluene® 350, at 50°C for 48 h. Aliquots 
of these samples were transferred into individual scintillation vials prior to analysis. With the 
cyanoacrylate biopsy procedures, the total recovery of the erythromycin was always within the 
limits, 100 ± 10%, as recommended by the OECD guidelines [11].  
Finite dose experiments  
For in vitro finite dose experiments, Franz cells should be dosed with a small amount of 
formulation that mimics as closely as possible the in vivo application of topical products. In the 
case of topical solutions, this has been recommended to be 10 µL/cm2 [11]. The volume of each 
test formulation, previously spiked with the radiolabelled drug, was applied on the full 
thickness skin sections placed between the donor and receiver chamber of each Franz cell (n = 
6). The cells were left in the waterbath un-occluded for 1 h; the absorption of the erythromycin 
from each formulation was tested with and without the application of external heat (skin 
temperature maintained at 45 °C for 10 minutes).  
At completion of the experiments at 1h, the multi-step recovery procedure described in the 
previous section with the exception that the cyanoacrylate biopsy was not performed, was used 
to assess the recovery of the drug from the SC, epidermis, dermis and receiver fluid.  
Data treatment and statistical analysis 
Statistical analysis of all the data was performed using Graphpad Prism software (version 7.0 
for Windows, La Jolla, USA). The in vitro skin permeation and penetration data was initially 
analysed for normality using the Shapiro-Wilk test to determine if the data was either 
parametric or non-parametric, where the determined p value was either p > 0.05 or p ≤ 0.05, 
respectively. The initial screening of the effect of temperature and the full range of penetration 
enhancers was performed using a two way ANOVA. Subsequent statistical comparisons were 
then performed using a one way ANOVA for parametric data or Kruskal-Wallis test for non-
parametric data. Post hoc comparisons were made with either Fishers LSD test or Dunn’s for 
parametric and non-parametric data respectively. Similarily pair wise comparisons were made 
either a t test or Mann Whitney U test as appropriate. Statistically significant differences were 
assumed at the 95% confidence level, i.e., when p < 0.05. 
Enhancement ratios were determined as:  
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Equation 1  
 
where Q (E) and Q (C) are the amount of the drug permeated into and across the skin when 
using enhancement strategies (i.e. heat, chemical penetration enhancers and heat with chemical 
penetration enhancers) and control (no heat or chemical penetration enhancers) respectively. 
Results  
Saturated solubility of erythromycin 
The solubility values of erythromycin in various chemical penetration enhancers, in addition 
to PBS pH 7.4 are reported in Table 1. Erythromycin showed high solubility in EtOH and 
Transcutol, intermediate solubility in DPPG, DPA and IPM and relatively lower solubility in 
PBS.  
 
Erythromycin in aqueous solution is most stable at pH around 7.0-7.5 [14]. As such PBS, in 
which the drug exhibits a solubility of 7.85 mg/mL at room temperature (Table 6-1) was used 
as a control formulation (no heat or chemical penetration enhancers) and as receiver fluid in 
the in vitro studies. Given its pKa of 8.9, erythromycin is expected to be almost fully ionised 
(96%) in the control formulation. The solubility of erythromycin in the receiver fluid, (PBS, 
pH 7.4) was also tested at 37 and 50 °C (Table 1) to provide confirmation that erythromycin 
concentrations in the receiver compartment always remained less than 10% of the saturated 
solubility of the drug, maintaining sink conditions during the in vitro permeation studies.  
In vitro erythromycin percutaneous absorption: effect of heat and chemical penetration 
enhancers  
In order to initially screen the effect of heat and chemical penetration enhancers on the skin 
absorption of erythromycin, the amount of erythromycin that accumulated in the epidermis and 
dermis along with that which had diffused to the receptor compartment from saturated solutions 
of the drug in EtOH, TC, IPM, DPPG, DPA and PBS was determined after 24 h, at both 32 and 
45 °C. The resulting data is shown in Figure 1.   As limited permeation of the drug into the 
receiver fluid was obtained from several of the test formulations, the drug was allowed to 
accumulate in the receiver fluid to levels above the LOQ and only a single time point sample 
was taken at the end of the experiment and therefore no permeation profiles are provided here. 
In general, considerably more erythromycin was found in the dermal layer in comparison to 
the epidermis or in the receiver fluid for many of the systems at 24h. The exception to this was 
for certain vehicles (DPPG, DPA, IPM and EtOH) at 45 °C for which delivery to the receiver 
fluid was greater than that to the dermis. These differences may relate to the capabilities of the 
enhancers to promote drug transport out of the hair follicles into the dermal tissue and receiver 
fluid. 
When considering the total amount of drug delivered in Figure 1, that is the quantity of 
erythromycin recovered from the epidermis, dermis and receiver fluid together, using a two 
way ANOVA, the effect of both heat and chemical penetration enhancers were found to 
significantly increase (p ≤ 0.05) erythromycin delivery. The analysis did not find an interaction 
between heat and chemical penetration enhancers indicating that the effectiveness of either 
strategy was not dependent on the other. However when combined together the total magnitude 
of drug delivery enhancement (~40-70-fold) provided by using both heat and chemical 
penetration enhancers was found to be greater than the use of heat (~3-12-fold) and chemical 
penetration enhancers (~6-17-fold) separately, suggesting that the combined penetration 
enhancing strategies work synergistically together. Amongst the chemical penetration 
enhancers tested, EtOH at 45 °C and TC at 45 °C provided the highest overall delivery of 
erythromycin, whereas at 32 °C, TC and IPM provided the highest delivery. 
Absorption of erythromycin into skin tissue following different durations of application: 1 h 
vs 24 h 
Given that erythromycin is a relatively large molecular weight molecule (RMM 733Da), it was 
hypothesised that it would only have low levels of transport across the continuous SC and 
would be more likely transported via appendages such as the hair follicles, which extend across 
the full thickness of the skin. Previous studies have suggested that the transport through such 
units should be rapid [7, 15, 16], consistent with a lower resistance to diffusion provided by 
the shunt routes in comparison to the continuous SC. The penetration of drugs such as, 
erythromycin through the hair follicles would therefore be expected to be relatively high at 
early time points. To confirm this hypothesis, the delivery of the drug from three different 
vehicles was tested at 1 h, in addition to 24 h, to help provide insight into erythromycin 
transport into skin. For this work, TC and DPPG, alone and in combination (50:50), were 
selected as vehicles for the drug. Of the hydrophobic chemical penetration enhancers tested 
(DPPG, IPM, DPA), DPPG was found to work best with heat as demonstrated by the 
enhancements in erythromycin delivery at the higher temperature, which were 6, 4 and 3-fold 
for DPPG, DPA and IPM respectively. DPPG should therefore be best to aid identification of 
the impact heat can have on drug delivery into and across the skin. Both of the hydrophilic 
enhancers tested, TC and ethanol were effective at delivering erythromycin into the skin, 
however TC was selected as it was found to provide higher drug concentrations in the dermis. 
Figure 2 shows the recovery of erythromycin from the skin strata and receiver fluid after both 
1 and 24 h following the application of erythromycin in the co-solvent system TC: DPPG 
(50:50) and the corresponding drug containing neat solvents TC and DPPG, at 32 °C. The 
penetration of the drug into the epidermis, dermis and receiver fluid under the same conditions 
but at a skin temperature of 45 °C is shown in Figure 3. What is initially apparent from Figures 
2 and 3 is that even after 1 hour the amount of drug in the dermis was considerable with 
statistical analysis indicating that this was equivalent to that obtained from the dermis at 24 
hours (p > 0.05) for all systems at 32 °C and TC and DPPG separately at 45 °C. A small increase 
was observed with TC:DPPG at 45°C. In contrast increased amounts of erythromycin were 
present in both the epidermis and receiver fluid for many of the systems at 24 hours in 
comparison to 1 hour. This suggests that erythromycin was able to penetrate rapidly in to the 
dermis, with subsequent slower permeation of the drug of the drug in to the epidermis (possibly 
via the continuous SC) and into the receiver fluid and occurring between 1 and 24 h. This seems 
to support the hypothesis that erythromycin is mainly delivered though the “low resistance” 
routes of permeation, the skin appendages, which originate in the dermis.  
As was previously observed with experiments run over 24 hours, increasing the temperature of 
the skin increased significantly (p ≤ 0.05) the overall delivery of erythromycin from each of 
the chemical penetration enhancers tested (4-6 fold) over 1 hour, compared to normal 
physiological skin temperature. The use of the mixed solvent system TC:DPPG appeared to 
show improved delivery into the skin strata in comparison to the neat solvents TG and DPPG, 
however this was not statistically significant except at 32 °C over 24 hours suggesting any 
benefit obtainable from using the mixed solvent system  is likely to be relatively small.  
Effect of different durations of heat exposure on erythromycin transport  
Application of heat to the skin for long periods, even for example 1 h is likely to limit its 
practical usefulness as an enhancement strategy.  However given that the data showed that the 
application of heat for only 1 h was effective at promoting erythromycin delivery into the skin 
it was decided to perform further investigations to understand whether it would be feasible to 
further reduce the duration of heat application, without compromising the effectiveness of 
using heat as an enhancement strategy. For this work erythromycin in DPPG was selected, as 
this solvent produced highest enhancement in drug delivery with heat (6-fold) compared to that 
calculated from TC (4-fold) and the co-solvent system TC: DPPG (4-fold) and as discussed 
previously should therefore offer the best opportunity to understand the effect of shorter 
durations of heat can have on skin transport.  
The effect of different heating durations, 5, and 10 minutes on erythromycin delivery from a 
suspension of the drug in DPPG is illustrated in Figure 4. Statistical comparison indicated that 
to observe the enhancement effect of heat (p ≤ 0.05) on drug transport, the systems had to be 
maintained at 45 °C for a period of only 10 min (ER: 5-fold), compared to being held 
continuously at 32 °C. No further significant increases in the amount of erythromycin absorbed 
into dermis were observed when the skin was heated for the whole 1 hour time course of the 
experiment (Figure 3).  
Localisation of erythromycin in the hair follicles: cyanoacrylate biopsy 
To confirm whether the drug was being delivered via the skin’s appendages a cyanoacrylate 
glue biopsy as a means to specifically quantify appendageal/follicular drug penetration, was 
performed. This procedure involves the application of cyanoacrylate glue to the skin; the glue 
is initially a free flowing liquid that can penetrate into the skin appendages and subsequently 
polymerises in the presence of air to form a solid mass. This solid mass can be removed from 
the skin to provide an indication of the amount of drug present in the appendages. 
The ‘differential stripping’ technique, where the cyanoacrylate biopsy procedure is performed 
after removing the SC was chosen to remove the possibility of drug content in the SC 
interfering with the assay. A saturated solution of erythromycin in DPPG was used and again 
the Franz cells were held at 45 °C for 10 minutes prior to being transferred to a water bath at 
32 °C for the remaining 50 minutes. The experiments were performed in a manner similar to 
that reported by Teichmann et al, and in addition a range of application times of the glue were 
tested to examine whether this affected the data obtained [17].  
The results are depicted in Figure 5 and show that following the removal of the SC and then 
the cyanoacrylate glue, the underlying viable epidermis did not contain any drug. Increasing 
the contact time between the cyanoacrylate glue and the skin from two to five minutes had no 
significant effect on the recovery of the active from the follicles, whereas when it was used for 
only 0.5 minutes a lower recovery was obtained. The amount of drug that was obtained from 
the cyanoacrylate biopsy was the same as that extracted from the viable epidermis when the 
conventional tape stripping procedure was used without the cyanoacrylate glue. There were no 
significant differences in the amount of erythromycin sampled from the dermis using the 
different tape stripping approaches. These data suggest that all of the erythromycin within the 
viable epidermis was within the appendages providing strong evidence that this was the main 
route of the drug into the skin.   
Finite dose experiments 
In the view of these promising data, which indicated that the use of a short duration of heat 
along with chemical penetration enhancers was effective at improving drug delivery into the 
skin via the follicular route, further experiments were designed to provide an understanding of 
the performance of a heated system under finite dose conditions. As the differential stripping 
process, although useful in helping identify the route of erythromycin transport into the skin, 
was not thought to fully quantify drug in the appendages, it was therefore decided to use the 
simpler conventional tape stripping method for these experiments. DPPG was again used as a 
formulation vehicle for erythromycin and additionally a mixed vehicle containing DPPG and 
ethanol was also investigated. Previously in the infinite dose experiments the hydrophilic 
chemical penetration enhancer, TC was used in combination with DPPG. However although 
this combined system showed good delivery of erythromycin into the skin it did not appear to 
offer significant advantages over DPPG alone. Ethanol was also seen to be a good penetration 
enhancer in the infinite dose studies, moreover it was thought that ethanol volatility could be 
beneficial in the finite dose investigations as with ethanol evaporation the thermodynamic 
activity of erythromycin in the formulation would be expected to increase, and could thereby 
further increase delivery of erythromycin into the skin.  
Erythromycin (at both 2% w/w and as saturated suspension) in DPPG and as a 2% solution in 
DPPG: ethanol (34:66) was applied to the skin with and without the application of a controlled 
level of heat (45 °C, for 10 min) over a 1 hour period. The results are shown in Figure 6 as 
absolute amounts of drug and to aid comparison between the formulations as a percentage of 
the applied dose in Table 2. If the total delivery is examined (SC + viable epidermis + dermis) 
a significant improvement in erythromycin delivery was observed with heat for each of the 
three formulations. Comparison between the three formulations indicated that there were no 
significant differences in overall delivery between them at the respective temperatures. 
However the use of heat provided significantly more delivery to the dermis from both the 
saturated and 2% solutions of erythromycin in DPPG (3.5 fold and 5.4 fold respectively), 
whereas the 2% DPPG:EtOH formulation did not significantly improve delivery of 
erythromycin to the dermis with heat but did provide 4.3 fold enhancement of delivery to the 
epidermis. The saturated solution of erythromycin in DPPG also provided significantly 
increased delivery to the SC at the elevated temperature (2.7 fold), whereas there were no 
significant differences between erythromycin delivery to the SC with heat were observed for 
the other two systems.  
 
The same data included in Figure 6 is shown as the percentage of the applied dose in Table 2.  
As the doses applied to the Franz cell from the saturated system in DPPG at 32 °C and 45 °C 
were different (the formulations were saturated the respective temperatures) it aids comparison 
between delivery at these two temperatures. The saturated solubilities of erythromycin at 32 
°C and 45 °C were 44 and 73 mg/mL respectively, and therefore a considerably higher dose 
was applied when the additional heat was used. However the data in Table 2 show that a greater 
proportion of the applied dose was delivered from the heated saturated erythromycin in DPPG 
system, indicating that the increased delivery obtained with heat is not simply a result of an 
increased dose having been applied. Table 2 also clearly shows that the 2% w/v loaded 
erythromycin formulations (both DPPG alone and DPPG:EtOH) delivered a greater proportion 
of the applied dose than the saturated system despite the thermodynamic activity of the drug in 
the formulation being lower at the higher temperature.   
 
Discussion 
The focus of this study was to examine whether heat in combination with chemical penetration 
enhancers could improve delivery of erythromycin to the skin and in particular via the follicular 
pathway. A skin temperature of 45°C was chosen to mimic conditions provided by a heated 
formulation as this is believed to be a relatively high but physiologically tolerable temperature. 
For example, the marketed system CHADD® (controlled heat aided drug delivery) is known to 
produce a maximum temperature on the skin of approximately 45 °C [18]. Technologies that 
can generate short durations of heat and can be contained within flexible packages are 
commercially available and other suitable phase change materials have been proposed for 
heating applications in topical drug delivery [19]. It should be possible to design drug delivery 
systems using these materials that are practical for patients to be able to use, an important 
consideration for topical treatments which often have poor patient adherence [20]. 
Follicular absorption is expected to be important not only for the management of conditions 
associated with these skin appendages but also for the absorption of relatively high molecular 
weight drugs including erythromycin [21]. That the differential tape stripping technique used 
here found no drug in the viable epidermis tissue following the cyanoacrylate biopsy provided 
a clear indication that the transport of erythromycin to the dermis had occurred via the 
appendageal route, rather than through traversing the continuous SC and viable epidermis. 
However as a similar amount of erythromycin was recovered from the dermis regardless of 
whether the glue was used or not, suggested that the biopsy did not sample the drug from the 
full length of the appendages which extend into the dermis. This is in agreement with previous 
work, which found that the cyanoacrylate glue enabled drug sampling from the appendageal 
infundibulum only, which constitutes the outermost 20% of the total hair follicle length [17]. 
The rapid delivery of erythromycin into the dermis and its enhancement with durations of heat 
as short as 10 minutes of heat again further supported the conclusion that erythromycin 
absorption largely occurred via the skin’s appendages given the relatively rapid absorption of 
this route [7, 15]. The subsequent, slower, delivery of erythromycin through to the receiver 
compartment, being consistent with slower transport out of the hair follicles and via other 
permeation pathways.  
Heat has been shown to be effective at promoting the skin transport of a range of drug 
molecules with differing physiochemical properties previously [4]. It is thought to improve 
drug diffusivity, as described through the Stokes- Einstein equation but may also have effects 
on drug partitioning and alter the skin’s properties for example rendering the intercellular lipids 
of the continuous SC more permeable [22]. In contrast literature on the ability of heat to work 
with different formulation vehicles is less well described nor has this method of enhancement 
previously been investigated for its effect specifically on follicular drug delivery. In this work 
heat was observed to improve delivery from both hydrophilic and hydrophobic vehicles. The 
beneficial effect of the chemical penetration enhancers alone on follicular erythromycin 
delivery likely relates to their ability to interact with sebum, in turn facilitating the 
solubilisation of the drug within the “sebum-enhancer” matrix [3], increasing follicular drug 
uptake. The existence of synergy between heat and chemical penetration enhancement is likely 
to be produced, if as well as directly assisting delivery of the drug into the SC, heat also 
improved delivery of the chemical penetration enhancer and the extent of enhancement 
observed is likely to be dependent on the properties of the particular chemical penetration 
enhancer and how it interacts with sebum [23, 24]. Combinations of hydrophilic and 
hydrophobic chemical penetration enhancers may provide synergistic improvements in drug 
delivery across skin, however the mixed solvent comprised of both DPPG and transcutol used 
here did not provide large improvements in delivery over the individual solvents with heat [25].  
To exploit any potential for synergy between combinations of chemical penetration enhancers 
and heat would require further work and most likely careful consideration of the properties of 
the drug and chemical penetration enhancers selected as such effects are not automatically 
obtained [26, 27]. 
Finite dosing mimics the in vivo situation more closely and provides increased confidence in 
the therapeutic success of prototype formulations for topical drug delivery. For the vehicle 
consisting of DPPG alone, similar enhancement ratios with heat were observed as with infinite 
dosing supporting the use of this approach for initially screening the vehicles. The similar total 
drug delivery obtained from the 2 % w/v loaded and saturated erythromycin systems in DPPG 
alone was surprising as the applied dose was considerably smaller for the 2% w/v loaded 
system. As the saturated systems were saturated at the temperature to which they were applied 
to the skin, the initial thermodynamic activity of the drug in the saturated vehicles are 
equivalent at the different temperatures, whereas that of the fixed dose 2% w/v loaded vehicle 
was lower, particularly for the heated system [28]. As both the heated systems delivered 
increased amounts of erythromycin and a greater percentage of the applied dose than the 
unheated systems, this indicated that the increased erythromycin skin absorption in the 
presence of heat increased cannot be explained through an increased dose being applied at the 
higher temperature. It also indicated that the reduction in drug thermodynamic activity for the 
2% w/v loaded vehicle that occurs at elevated temperature did not negate the beneficial impact 
of heat in promoting drug uptake into skin. The 2 % w/v loaded DPPG:EtOH vehicle was 
designed to make use of ethanol’s volatility so that any reduction in erythromycin 
thermodynamic activity in a fixed dose formulation with increased temperature could be 
compensated for, as the drug’s thermodynamic activity would be raised as the solvent 
evaporated [29, 30]. Although this formulation did work with heat, it did not increase total 
erythromycin delivery above that of the 2% w/v DPPG formulation. Moreover differences were 
observed in the distribution of erythromycin in the skin, with the heated DPPG:EtOH 
formulation providing significant improvements in delivery to the epidermis in particular, but 
not to the dermis. Consequently this formulation approach utilizing a volatile solvent appears 
to be less suitable for working with heat to provide optimal erythromycin delivery. It is possible 
that evaporation of ethanol from the formulation may have induced crystallisation of the drug 
within the skin, reducing its delivery to the deeper dermal tissues [31].  The increased drug 
delivery observed with heat is likely to be related to other effects such as more favourable 
chemical penetration enhancer uptake into skin [32, 33]. It has previously been shown when 
chemical penetration enhancers are used, improved drug delivery may be obtained from lower 
levels of drug saturation if this is associated with improved delivery of the chemical penetration 
enhancer [23]. Similar behaviour may occur with heat, allowing equivalent delivery to be 
provided by subsaturated (2% w/w) and saturated erythromycin formulation vehicles.  
The relatively large molecular weight of erythromycin, the model drug used here may have 
disposed its delivery towards targeting of the follicular route of absorption as it is unlikely to 
be well absorbed through the continuous SC. However the human scrotal skin used in this study 
is generally considered to be considerably more permeable than that from other body sites [34], 
despite the density of hair follicles and other appendages being comparatively lower than that 
of other body areas [35].  This suggests that the data reported may underestimate the impact of 
heat and chemical penetration enhancers on follicular absorption at body sites with a higher 
density of hair follicles such as the face or scalp which are commonly associated with 
conditions such as acne vulgaris and alopecia. For other molecules that exhibit better 
absorption via the continuous SC, short durations of heat are likely to still be of benefit in 
preferentially directing drug delivery to the hair follicles through enhancing delivery through 
this rapid transport pathway to a greater extent than through the SC. 
Most of the previous studies that have investigated the effects of heat on drug transport across 
skin or model membranes have used water baths as a model system to simulate heat producing 
formulations as was done here [4, 5]. Further work investigating the use of heat generating 
formulations materials to improve topical drug delivery will be beneficial not just to more 
closely mimic the in vivo situation but also to beneficially utilize the ‘Soret effect’, where 
molecules exhibit a drift mobility along a thermal gradient in addition to Brownian diffusion 
[36, 37]. Applying heat to the skin in vivo is thought to increase cutaneous blood flow [38] 
which could increase drug clearance from the site of action, decreasing topical effectiveness. 
However the success of a heated topical patch containing lidocaine and tetracaine suggest that 
this is not necessarily an overriding consideration [39, 40]. As such it is likely that the increases 
in drug absorption into the skin that can be produced by heat and chemical penetration 
enhancers are likely to be capable of improving clinical outcomes of therapeutic treatment. In 
conclusion the results from this work have demonstrated for the first time the positive impact 
heat can have on follicular drug absorption into the skin. The application of a moderate level 
of heat in combination with penetration enhancers was able to synergistically increase 
absorption of the selected model drug, erythromycin. Moreover durations of exposure to heat 
as short as 10 minutes were sufficient to improve follicular delivery supporting the suitability 
and highlighting the potential of this approach to develop practical, improved topical treatments 
for the management of skin conditions. 
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Figure 1. Mean amount of erythromycin recovered from epidermis, dermis and receiver fluid 
following the application of a saturated solution of erythromycin in DPPG, DPA, IPM, EtOH, 
TC and PBS, at 32 and 45 ºC, after 24 h (mean ± SE, n=6). * indicates a significantly lower 
total absorption (epidermis, dermis and receiver fluid combined) for experiments conducted at 
45 °C compare to those conducted at 45 °C.  
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Figure 2. Mean cumulative amount of erythromycin recovered from epidermis, dermis and 
receiver following the application of saturated solution of the drug in TC: DPPG (50:50), DPPG 
and TC, at 32 ºC, after 1 and 24 h (mean ± SE, n=6). ns indicates no significant difference in 
dermal absorption at 1 hour compared to that from the same vehicle at 24 hours. 
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Figure 3. Mean cumulative amount of erythromycin recovered from epidermis, dermis and 
receiver following the application of saturated solution of the drug in TC: DPPG (50:50), DPPG 
and TC, at 45 ºC, after 1 and 24 h (mean ± SE, n=6). * indicates a significantly higher dermal 
absorption at 1 hour compared to that from the same vehicle at 24 hours.  
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Figure 4. Effect of the duration of heat exposure on the delivery of erythromycin to the 
epidermis and dermis, from saturated solutions of the drug in DPPG after 1 hour (mean ± SE, 
n=6). * indicates a significantly higher total absorption (epidermis and dermis combined) at 1 
hour compared to the erythromycin in DPPG formulation at 32°C.  
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Figure 5. Comparison (a) of the amount of erythromycin recovered from the viable epidermis, 
dermis and appendages when using both conventional (labelled as “no glue”) and differential 
tape stripping procedures (glue, applied for 0.5, 2 and 5 min),  1 h after the application of a 
saturated solution of the drug in DPPG, at 45°C (for 10 min (mean with range, n=3). The glue 
was applied for different durations, after removing the SC. * indicates a significantly lower 
recovery than was obtained when the cyanoacrylate biopsy was not used.  
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Figure 6. Total mean amount of erythromycin recovered from the skin, and that from the 
separate skin layers the SC, epidermis and dermis 1 h after the application of a finite dose of a 
2% w/v solution and saturated suspension of the drug in DPPG and a 2% solution in DPPG: 
EtOH (34:66), with and without application of heat (45 °C for 10 min) (mean + SE, n=4-6). * 
indicates a significant difference between the experiment conducted at 32 °C for one hour and 
that where the Franz cell was exposed to 45 °C for 10 minutes, before being transferred to the 
32 °C conditions.   
 
 
 
 
 
 
 
 Table 1. Erythromycin saturated solubility values at room temperature unless otherwise stated. 
Values are reported as the mean ± range (n=3). 
Solvent Drug Solubility (mg/mL) 
EtOH 560.7 (± 7.6) 
Transcutol 477.2 (± 5.4) 
IPM 23.6 (± 1.4) 
DPPG 43.5 (± 1.8) 
DPA 62.4 (± 2.2) 
PBS 7.85 (± 0.13) 
PBS (37°C) 8.24 (± 0.21) 
PBS (50°C) 9.72 (± 0.19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Percentage of applied erythromycin recovered from skin layers 1 h post application of all solvent systems. Values are reported as the 
mean ± SEM (n=4-6). 
Formulation vehicle and conditions 
Total drug 
absorption (%) 
Stratum corneum drug 
content (%) 
Viable epidermis drug 
content (%) 
Dermis drug 
content (%)  
2% w/w DPPG at 32°C 15.36 (± 3.94) 7.81 (± 1.41) 5.36 (± 2.67) 2.28 (± 0.36) 
2% w/w DPPG at 45 °C for 10 min 28.51 (± 5.55)* 9.87 (± 2.17) 6.38 (± 2.13) 12.26 (± 3.65)* 
Sat sol in DPPG at 32°C 3.54 (± 0.70) 1.49 (± 0.22) 0.97 (± 0.42) 1.09 (± 0.28) 
 Sat sol in DPPG at 45 °C for 10 min 10.00 (± 0.91)* 4.20 (± 0.54)* 1.73 (± 0.57) 4.07 (± 0.39)* 
2% w/w DPPG: EtOH at 32°C 18.75 (± 2.70) 9.87 (± 0.68) 3.92 (± 0.92) 4.96 (± 2.02) 
2% w/w DPPG: EtOH at 45 °C for 10 min 36.08 (± 3.12)* 12.94 (± 1.61) 16.71 (± 2.34)* 6.43 (± 1.96) 
 
 
